Recent legislative reforms to abortion law in New South Wales gave rise to vigorous public and media discourse. This post seeks to provide some clarifications across several related but legally and ethically distinct domains in health law.
On BioEdge, Dr Patrick Foong and I quickly run through the bioethical perturbations that have come with the relatively rapid approval of Casgevy, the first-ever approved genome-editing therapy that utilises CRISPR/Cas 9. In some ways, it could be said that Casgevy is the first-ever approved genome therapy ‘full-stop’, because other categories of gene therapy have […]
In late November, I presented a paper via video link to the Australasian Association of Bioethics and Heath Law (AABHL) on ‘risk-based regulation.’ The abstract for that paper was as follows: What risk? A critical analysis of risk-based regulation of therapeutic goods, from stem cell medicine to osseointegration devices Therapeutic goods (medicines, biologicals and devices) […]
The chimeric monkey experiment I was quoted in this article today regarding a newly published study in Cell that demonstrates, in the author’s words, that ‘mammalian pluripotent stem cells possess preimplantation embryonic cell-like (naive) pluripotency.’ As the summary notes, this discovery about embryonic stem cells can now be said to have been demonstrated experimentally through […]
After a long journey that should have been no surprise whatsoever (not when one looks at the scale and size of this volume), a book chapter I authored with Emeritus Distinguished Prof Dianne Nicol from the University of Tasmania’s Centre for Law and Genetics, way back in 2021, has now been published. The chapter deals […]